Sumitomo Mitsui Trust Group
MCRB icon

Sumitomo Mitsui Trust Group’s Seres Therapeutics MCRB Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34,839
Closed -$2.39M – 1229
2022
Q2 		$2.39M Sell
34,839
-1,524
-4% -$131K ﹤0.01% 932
2022
Q1 		$5.18M Sell
36,363
-2,913
-7% -$448K ﹤0.01% 850
2021
Q4 		$6.54M Sell
39,276
-4,470
-10% -$710K ﹤0.01% 813
2021
Q3 		$6.09M Sell
43,746
-220,752
-83% -$43.2M ﹤0.01% 826
2021
Q2 		$126M Sell
264,498
-33,008
-11% -$13.9M 0.07% 295
2021
Q1 		$123M Buy
297,506
+6,326
+2% +$2.91M 0.08% 298
2020
Q4 		$143M Buy
291,180
+14,596
+5% +$8.55M 0.09% 249
2020
Q3 		$157M Sell
276,584
-93,428
-25% -$31.1M 0.11% 207
2020
Q2 		$35.2M Sell
370,012
-50,904
-12% -$4.47M 0.02% 583
2020
Q1 		$30.1M Buy
420,916
+7,255
+2% +$487K 0.03% 563
2019
Q4 		$28.5M Buy
413,661
+30,563
+8% +$2.27M 0.02% 620
2019
Q3 		$30.7M Buy
383,098
+140,944
+58% +$9.31M 0.03% 573
2019
Q2 		$15.6M Buy
242,154
+202,094
+504% +$19.2M 0.01% 690
2019
Q1 		$5.5M Buy
+40,060
New +$4.88M 0.01% 719

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group's MCRB Position: Q3 2022 in Review

Sumitomo Mitsui Trust Group sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 34,839 shares — an estimated $2.39M sold.

Sumitomo Mitsui Trust Group first reported a position in MCRB in Q1 2019 and held it in 14 quarters. The position peaked at $157M in Q3 2020. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • Sumitomo Mitsui Trust Group reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 34,839 Seres Therapeutics shares in Q3 2022, an estimated $2.39M.
  • Sumitomo Mitsui Trust Group first reported a position in Seres Therapeutics in Q1 2019 and held it in 14 quarters.
  • Sumitomo Mitsui Trust Group's Seres Therapeutics position peaked at $157M in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2022, filed 21 Oct 2022.